UNM News, Dec. 7, 2011 – UNM News, Nov. 23, 2011 In this newscast, UNM has chosen five finalists for the job of university president. UNM journalism student Stephanie Hoover describes the latest UNM research findings on breast cancer treatment. Pol Nikulin and Lindsay Douglass report on the precarious state of the aquifer that has historically met Albuquerque’s water needs. Reporter Anthony Roibal presents the latest figures that rank New Mexico as the number one state for deaths from drug overdoses. Barron Jones has a video pictorial from New Mexico’s Bosque del Apache bird sanctuary. Megan Eichhorn and Lindsay Douglas covered the UNM Queer-Straight Alliance’s third annual Drag Show. And Katie Fosterling filed a report on Mexican mask maker Felipe Horta and his trip to UNM’s Latin American and Iberian Institute. Newscast runs 15:34. Anchors: Adam Camp and Miriam Belin. Producer: Miriam Belin. UNM News is a web-based news site produced primarily by students in the Department of Communication and Journalism at the University of New Mexico to serve students, faculty and staff. More stories, newscasts and archives are available at the UNM News website: unmnews.wordpress.com
H3 Biomedicine completes Cambridge expansion
Filed under:drug treatment news 2011
Earlier this year, H3 Biomedicine landed a cooperative deal with Cambridge-based Horizon Discovery Ltd. to develop a panel of cancer drug targets, and two months before it signed that deal, H3 signed a three-year licensing deal with Compendia … Read more on Mass High Tech
Less acetaminophen in each tablet of Vicodin
Filed under:drug treatment news 2011
In January 2011, the US Food and Drug Administration (FDA) asked drug companies to limit the amount of acetaminophen in all prescription medicines to 325 mg per tablet. This would … If they do, discuss with your doctor other treatment options. Read … Read more on Philadelphia Inquirer (blog)
Antisense Therapeutics grows cash position with R&D tax rebates
Filed under:drug treatment news 2011
… development as a treatment for the growth hormone disorder, acromegaly, and is approaching phase two clinical trials. The cash refund payments will cover three years from 1 July 2011, with around $ 70,000 of the total relating to the 2011-12 … Read more on Proactive Investors Australia